在第三期试验中, Eli Lilly 的复原降低了糖尿病A1C的2. 0%,并导致平均体重减轻16. 8%,符合所有终点但副作用很少. Eli Lilly's retatrutide reduced diabetes A1C by 2.0% and caused 16.8% average weight loss in a Phase 3 trial, meeting all endpoints with few side effects.

伊利·莉莱的三重激动剂复原在2型糖尿病3期试验中显示出强烈的结果,降低A1C高达2. 0%,并在40周内平均减肥16. 8%,没有平稳. Eli Lilly’s investigational triple agonist retatrutide showed strong results in a Phase 3 trial for type 2 diabetes, reducing A1C by up to 2.0% and causing an average weight loss of 16.8% over 40 weeks, with no plateau. 药物满足所有主要和次要终点,改善了关键心血管风险因素,并且由于副作用而导致的停用率很低. The drug met all primary and secondary endpoints, improved key cardiovascular risk factors, and had a low discontinuation rate due to side effects. 常见的副作用包括恶心,腹和吐,主要是在剂量升级期间. Common side effects included nausea, diarrhea, and vomiting, mostly during dose escalation. 针对GIP,GLP-1和葡萄糖受体的雷塔特鲁正在多项关于肥胖症,肝病和其他代谢疾病的试验中进行研究. Retatrutide, which targets GIP, GLP-1, and glucagon receptors, is being studied in multiple trials for obesity, liver disease, and other metabolic conditions. 它仍在研究中,尚未获得批准. It remains investigational and is not yet approved.